SCHEMBL208025

SCHEMBL208025

c1ccc2c(c1)Sc1ccccc1N2CCCCCCN1c2ccccc2Sc2ccccc21

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 1/20 0.79
KDM1A O60341 11/20 0.68
SIGMAR1 Q99720 3/20 0.68
SLC22A1 O15245 1/20 0.68
PRNP P04156 1/20 0.68
TP53 P04637 1/20 0.68
CYP1A2 P05177 1/20 0.68
ADRB2 P07550 1/20 0.68
CHRM2 P08172 1/20 0.68
CHRM4 P08173 1/20 0.68
HTR1A P08908 1/20 0.68
CHRM5 P08912 1/20 0.68
ADRA2A P08913 1/20 0.68
CYP2D6 P10635 1/20 0.68
CHRM1 P11229 1/20 0.68
DRD2 P14416 1/20 0.68
TSHR P16473 1/20 0.68
ADRA2B P18089 1/20 0.68
ADRA2C P18825 1/20 0.68
CHRM3 P20309 1/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28347553 0.91 PIM1 (0.67) PIM1KDM1ASIGMAR1SLC22A1PRNP
SCHEMBL11402576 0.91 PIM1 (0.67) PIM1KDM1ASIGMAR1SLC22A1PRNP
SCHEMBL29557345 0.91 PIM1 (0.67) PIM1KDM1ASIGMAR1SLC22A1PRNP
SCHEMBL2784918 0.91 PIM1 (0.67) PIM1KDM1ASIGMAR1SLC22A1PRNP
SCHEMBL16616978 0.91 PIM1 (0.67) PIM1KDM1ASIGMAR1SLC22A1PRNP
SCHEMBL7397164 0.91 PIM1 (0.67) PIM1KDM1ASIGMAR1SLC22A1PRNP
SCHEMBL30950675 0.91 PIM1 (0.67) PIM1KDM1ASIGMAR1SLC22A1PRNP
SCHEMBL31302971 0.91 PIM1 (0.67) PIM1KDM1ASIGMAR1SLC22A1PRNP
SCHEMBL342329 0.91 PIM1 (0.67) PIM1KDM1ASIGMAR1SLC22A1PRNP
SCHEMBL4192605 0.91 PIM1 (0.67) PIM1KDM1ASIGMAR1SLC22A1PRNP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7445877-B2 Charge transport materials having a central disulfane linkage SAMSUNG ELECTRONICS CO., LTD. (KR) 2008-11-04 US claimed
US-7326506-B2 Bridged charge transport materials having a central sulfur atom linkage SAMSUNG ELECTRONICS CO., LTD. (KR) 2008-02-05 US claimed
EP-1600821-B1 Bridged charge transport materials having a central sulfur atom linkage SAMSUNG ELECTRONICS CO LTD (KR) 2007-02-28 EP claimed
US-20050277038-A1 Charge transport materials having a central disulfane linkage S-PRINTING SOLUTION CO., LTD. (KR) 2005-12-15 US claimed
US-20050266329-A1 Bridged charge transport materials having a central sulfur atom linkage S-PRINTING SOLUTION CO., LTD. (KR) 2005-12-01 US claimed
EP-1600821-A1 Bridged charge transport materials having a central sulfur atom linkage Samsung Electronics Co., Ltd. (KR) 2005-11-30 EP claimed
US-8193372-B2 Phosphothiophene and phosphothiazole HCV polymerase inhibitors IDENIX PHARMACEUTICALS, INC. (US) 2012-06-05 US disclosed
EP-2403860-A2 PHOSPHOTHIOPHENE AND PHOSPHOTHIAZOLE AS HCV POLYMERASE INHIBITORS IDENIX Pharmaceuticals, Inc. (US) 2012-01-11 EP disclosed
US-8088785-B2 Therapeutic compound and treatments MEDISYN TECHNOLOGIES, INC. (US) 2012-01-03 US disclosed
US-20100233123-A1 PHOSPHOTHIOPHENE AND PHOSPHOTHIAZOLE HCV POLYMERASE INHIBITORS IDENIX PHARMACEUTICALS, INC. (US) 2010-09-16 US disclosed
WO-2010101967-A2 PHOSPHOTHIOPHENE AND PHOSPHOTHIAZOLE HCV POLYMERASE INHIBITORS IDENIX PHARMACEUTICALS, INC. (US) 2010-09-10 WO disclosed
US-20100137253-A1 THERAPEUTIC COMPOUND AND TREATMENTS MEDISYN TECHNOLOGIES, INC. (US) 2010-06-03 US disclosed
US-7652029-B2 Therapeutic compound and treatments MEDISYN TECHNOLOGIES, INC. (US) 2010-01-26 US disclosed
EP-1465020-A2 Organophotoreceptor with a charge transport compound having an epoxy group Samsung Electronics Co., Ltd. (KR) 2004-10-06 EP disclosed
US-20040191655-A1 Polymeric charge transport compositions S-PRINTING SOLUTION CO., LTD. (KR) 2004-09-30 US disclosed
US-20040170910-A1 Organophotoreceptor with a charge transport material having two hydrazone groups S-PRINTING SOLUTION CO., LTD. (KR) 2004-09-02 US disclosed
US-20040170909-A1 Organophotoreceptor with a charge transport material having two (9-fluorenylidene) malononitrile groups S-PRINTING SOLUTION CO., LTD. (KR) 2004-09-02 US disclosed
EP-1452924-A1 Organophotoreceptor with charge transport material having two hydrazone groups Samsung Electronics Co., Ltd. (KR) 2004-09-01 EP disclosed
EP-1452925-A1 Organophotoreceptor with a charge transport material having two (9-fluorenylidene) malononitrile groups Samsung Electronics Co., Ltd. (KR) 2004-09-01 EP disclosed
US-20040161685-A1 Organophotoreceptor with a charge transport compound having an epoxy group S-PRINTING SOLUTION CO., LTD. (KR) 2004-08-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040170909-A1 Organophotoreceptor with a charge transport material having two (9-fluorenylidene) malononitrile groups SLC39A14, SLC37A4, SLC39A7 PIM1 4264/4885KDM1A 3470/4885SIGMAR1 892/4885
US-20040170910-A1 Organophotoreceptor with a charge transport material having two hydrazone groups SLC16A7, SLC43A1, SLC16A8 PIM1 4621/4885KDM1A 3033/4885SIGMAR1 1022/4885
US-20100137253-A1 THERAPEUTIC COMPOUND AND TREATMENTS MDH1, MDH2, MBOAT7 PIM1 4242/4885KDM1A 4853/4885SIGMAR1 4083/4885
US-20050266329-A1 Bridged charge transport materials having a central sulfur atom linkage NR2E3, NR4A2, NR2C2 PIM1 4644/4885KDM1A 3378/4885SIGMAR1 1117/4885
US-20100233123-A1 PHOSPHOTHIOPHENE AND PHOSPHOTHIAZOLE HCV POLYMERASE INHIBITORS PPP3CB, POLR2E, PSAT1 PIM1 1981/4885KDM1A 4243/4885SIGMAR1 1381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.